Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2019

28.06.2019 | Brief Report

Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions: evidence from an international multi-centre study

verfasst von: Antonio Ponti, Guglielmo Ronco, Elsebeth Lynge, Mariano Tomatis, Ahti Anttila, Nieves Ascunce, Mireille Broeders, Jean-Luc Bulliard, Isabella Castellano, Patricia Fitzpatrick, Alfonso Frigerio, Solveig Hofvind, Ondřej Májek, Nereo Segnan, Stephen Taplin, the ICSN DCIS Working Group

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Nuclear grade is an important indicator of the biological behaviour of ductal carcinoma in situ (DCIS). De-escalation of treatment has been suggested for low-grade DCIS. Our aim is to estimate the relative rate of progression of DCIS by nuclear grade by analysing the distribution of nuclear grade by detection at initial or subsequent screening.

Methods

We asked International Cancer Screening Network sites to complete, based on their screening and clinical databases, an aggregated data file on DCIS detection, diagnosis and treatment.

Results

Eleven screening programs reported 5068 screen-detected pure DCIS in nearly 7 million screening tests in women 50–69 years of age. For all programs combined, low-grade DCIS were 20.1% (range 11.4–31.8%) of graded DCIS, intermediate grade 31.0% and high grade 48.9%. Detection rates decreased more steeply from initial to subsequent screening in low compared to high-grade DCIS: the ratios of subsequent to initial detection rates were 0.39 for low grade, 0.51 for intermediate grade, and 0.75 for high grade (p < 0.001).

Conclusions

These results suggest that the duration of the preclinical detectable phase is longer for low than for high-grade DCIS. The findings from this large multi-centre, international study emphasize that the management of low-grade DCIS should be carefully scrutinized in order to minimize overtreatment of screen-detected slow-growing or indolent lesions. The high variation by site in the proportion of low grade suggests that further pathology standardization and training would be beneficial.
Literatur
1.
Zurück zum Zitat Duffy SW, Dibden A, Michalopoulos D et al (2016) Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncol 17(1):109–114CrossRefPubMedPubMedCentral Duffy SW, Dibden A, Michalopoulos D et al (2016) Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncol 17(1):109–114CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Jacklyn G, Morrel S, McGeechan K et al (2018) Carcinoma in situ of the breast in New South Wales, Australia: current status and trends over the last 40 year. The Breast 37:170–178CrossRefPubMed Jacklyn G, Morrel S, McGeechan K et al (2018) Carcinoma in situ of the breast in New South Wales, Australia: current status and trends over the last 40 year. The Breast 37:170–178CrossRefPubMed
3.
Zurück zum Zitat van Luijt PA, Heijnsdijk EAM, Fracheboud J et al (2016) The distribution of ductal carcinoma in situ grade in 4232 women and its impact on overdiagnosis in breast cancer screening. Breast Cancer Res 18:47CrossRefPubMedPubMedCentral van Luijt PA, Heijnsdijk EAM, Fracheboud J et al (2016) The distribution of ductal carcinoma in situ grade in 4232 women and its impact on overdiagnosis in breast cancer screening. Breast Cancer Res 18:47CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Ozanne EM, Shieh Y, Barnes J et al (2011) Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat 129:165–173CrossRefPubMed Ozanne EM, Shieh Y, Barnes J et al (2011) Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat 129:165–173CrossRefPubMed
5.
Zurück zum Zitat Nicholson S, Hanby A, Clements K et al (2015) Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK HHS Breast Screening Programme audit of screen detected DCIS. Eur J Surg Oncol 41:86–93CrossRefPubMed Nicholson S, Hanby A, Clements K et al (2015) Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK HHS Breast Screening Programme audit of screen detected DCIS. Eur J Surg Oncol 41:86–93CrossRefPubMed
6.
Zurück zum Zitat Mokbel K, Cutuli B (2006) Heterogeneity of ductal carcinoma in situ and its effects on management. Lancet 7:756–765CrossRef Mokbel K, Cutuli B (2006) Heterogeneity of ductal carcinoma in situ and its effects on management. Lancet 7:756–765CrossRef
7.
Zurück zum Zitat Wallis MG, Clements K, Kearins O et al (2012) The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer 106:1611–1617CrossRefPubMedPubMedCentral Wallis MG, Clements K, Kearins O et al (2012) The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer 106:1611–1617CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Esserman L, Yau C (2015) Rethinking the standard for ductal carcinoma in situ treatment. JAMA Oncol 1(7):881–883CrossRefPubMed Esserman L, Yau C (2015) Rethinking the standard for ductal carcinoma in situ treatment. JAMA Oncol 1(7):881–883CrossRefPubMed
10.
Zurück zum Zitat Gagliardi AR, Wright FC, Look Hong NJ et al (2019) National consensus recommendations on patient-centred care for ductal carcinoma in situ. Breast Cancer Res Treat 174:561–570CrossRefPubMedPubMedCentral Gagliardi AR, Wright FC, Look Hong NJ et al (2019) National consensus recommendations on patient-centred care for ductal carcinoma in situ. Breast Cancer Res Treat 174:561–570CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Freeman J, Hutchinson GB (1980) Prevalence, incidence and duration. Am J Epidemiol 112:707–723CrossRefPubMed Freeman J, Hutchinson GB (1980) Prevalence, incidence and duration. Am J Epidemiol 112:707–723CrossRefPubMed
12.
Zurück zum Zitat Morrison AS (1985) Screening in chronic disease, 1st edn. Oxford University Press, New York and Oxford, p 38 Morrison AS (1985) Screening in chronic disease, 1st edn. Oxford University Press, New York and Oxford, p 38
13.
Zurück zum Zitat Lynge E, Ponti A, James T et al (2014) Variation in the detection of ductal carcinoma in situ (DCIS) during screening mammography. A survey within the International Cancer Screening Network (ICSN). Eur J Cancer 50(1):185–192CrossRefPubMed Lynge E, Ponti A, James T et al (2014) Variation in the detection of ductal carcinoma in situ (DCIS) during screening mammography. A survey within the International Cancer Screening Network (ICSN). Eur J Cancer 50(1):185–192CrossRefPubMed
14.
Zurück zum Zitat Ponti A, Lynge E, James T et al (2014) International variation in management of screen-detected ductal carcinoma in situ of the breast. Eur J Cancer 50(15):2695–2704CrossRefPubMedPubMedCentral Ponti A, Lynge E, James T et al (2014) International variation in management of screen-detected ductal carcinoma in situ of the breast. Eur J Cancer 50(15):2695–2704CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Holland R, Peterse JL, Millis RR et al (1994) Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11(3):167–180PubMed Holland R, Peterse JL, Millis RR et al (1994) Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11(3):167–180PubMed
16.
Zurück zum Zitat Silverstein MJ, Lagios MD, Craig PH et al (1996) A prognostic index for ductal carcinoma in situ of the breast. Cancer 77:2267–2274CrossRefPubMed Silverstein MJ, Lagios MD, Craig PH et al (1996) A prognostic index for ductal carcinoma in situ of the breast. Cancer 77:2267–2274CrossRefPubMed
17.
Zurück zum Zitat Weigel S, Khil L, Hense HW et al (2018) Detection rates of ductal carcinoma in situ with biennal digital mammography screening: radiologic findings support pathologic model of tumor progression. Radiology 286:424–432CrossRefPubMed Weigel S, Khil L, Hense HW et al (2018) Detection rates of ductal carcinoma in situ with biennal digital mammography screening: radiologic findings support pathologic model of tumor progression. Radiology 286:424–432CrossRefPubMed
18.
Zurück zum Zitat Weigel S, Heindel W, Heidinger O (2013) Digital mammography screening: association between detection rate and nuclear grade of ductal carcinoma in situ. Radiology 271:38–44CrossRefPubMed Weigel S, Heindel W, Heidinger O (2013) Digital mammography screening: association between detection rate and nuclear grade of ductal carcinoma in situ. Radiology 271:38–44CrossRefPubMed
19.
Zurück zum Zitat Weigel S, Hense HW, Heidrich J et al (2016) Does age influence the detection rates of low, intermediate and high grade ductal carcinoma in situ? Radiology 278:707–713CrossRefPubMed Weigel S, Hense HW, Heidrich J et al (2016) Does age influence the detection rates of low, intermediate and high grade ductal carcinoma in situ? Radiology 278:707–713CrossRefPubMed
20.
Zurück zum Zitat Sagara Y, Mallory MA, Wong S et al (2015) Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study. JAMA Surg 150(8):739–745CrossRefPubMed Sagara Y, Mallory MA, Wong S et al (2015) Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study. JAMA Surg 150(8):739–745CrossRefPubMed
21.
Zurück zum Zitat Segnan N, Minozzi S, Armaroli P et al (2016) Epidemiologic evidence of slow growing, non-progressive or regressive breast cancer: a systematic review. Int J Cancer 139(3):554–573CrossRefPubMed Segnan N, Minozzi S, Armaroli P et al (2016) Epidemiologic evidence of slow growing, non-progressive or regressive breast cancer: a systematic review. Int J Cancer 139(3):554–573CrossRefPubMed
22.
Zurück zum Zitat van Dooijeweert C, van Diest PJ, Willems SM et al (2019) Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands. Breast Cancer Res Treat 174(2):479–488CrossRefPubMed van Dooijeweert C, van Diest PJ, Willems SM et al (2019) Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands. Breast Cancer Res Treat 174(2):479–488CrossRefPubMed
Metadaten
Titel
Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions: evidence from an international multi-centre study
verfasst von
Antonio Ponti
Guglielmo Ronco
Elsebeth Lynge
Mariano Tomatis
Ahti Anttila
Nieves Ascunce
Mireille Broeders
Jean-Luc Bulliard
Isabella Castellano
Patricia Fitzpatrick
Alfonso Frigerio
Solveig Hofvind
Ondřej Májek
Nereo Segnan
Stephen Taplin
the ICSN DCIS Working Group
Publikationsdatum
28.06.2019
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05333-6

Weitere Artikel der Ausgabe 3/2019

Breast Cancer Research and Treatment 3/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.